Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 133, Issue 2, Pages 505-513Publisher
WILEY
DOI: 10.1002/ijc.28034
Keywords
HGF; EGFR-TKI resistance; PI3K; mTOR; EGFR mutation
Categories
Funding
- Ministry of Education, Science, Sports, and Culture of Japan [24390209, 22112010, 23790902, 11019957]
- P-Direct
- Chugai Pharmaceutical Co., Ltd.
- Kyowa Hakko Kirin Co., Ltd.
- Eisai Co., Ltd.
- Grants-in-Aid for Scientific Research [23790902, 22112010, 24390209, 23790903, 23790327] Funding Source: KAKEN
Ask authors/readers for more resources
Acquired resistance to epidermal growth factor receptortyrosine kinase inhibitors (EGFRTKIs), such as gefitinib and erlotinib, is a critical problem in the management of patients with EGFR mutant lung cancer. Several mechanisms have been reported involved in this acquired resistance, including hepatocyte growth factor (HGF) activation of an alternative pathway. PI3K and mTOR are downstream molecules of receptor tyrosine kinases, such as EGFR and Met, and are thought to be ideal targets for controlling various tumor types. We assessed whether BEZ235, a dual inhibitor of PI3K and mTOR, could overcome the EGFRTKI resistance induced by HGF in an EGFR mutant lung cancer model. Exogenous and endogenous HGF triggered resistance to erlotinib in the PC-9 and HCC827, EGFR mutant lung cancer cell lines. BEZ235 alone inhibited the viability of PC-9 and HCC827 cells in vitro, irrespective of the presence or the absence of HGF. Using a xenograft model of severe combined immunodeficient mice with HGF-gene-transfected PC-9 cells (PC-9/HGF), we found that BEZ235 inhibited tumor growth, whereas erlotinib did not. BEZ235 monotherapy also inhibited the phosphorylation of Akt and p70S6K/S6RP, downstream molecules of PI3K and mTOR, respectively, as well as suppressing tumor-cell proliferation and angiogenesis of PC-9/HGF tumors. These results suggest that BEZ235, even as monotherapy, may be useful in managing HGF-induced EGFRTKI resistance in EGFR mutant lung cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available